# US 2025/0134851 A1 · Alternative novel material to botulinum neurotoxin and preparation method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0134851 A1
- Document ID: US20250134851A1
- Status: Published application
- Kind: A1
- Application number: 18/690,763
- Filed: 2022-08-24
- Published: 2025-05-01
- Earliest claimed: 2021-09-17
- Assignees: Intron Biotechnology, Inc.
- Applicants: Intron Biotechnology, Inc.
- Inventors: Seong Jun Yoon; An Sung Kwon; Soo Youn Jun; Ji Sung Park; Seon Ho Park; Sang Hyeon Kang
- Web page: https://patentgrep.com/patent/US20250134851A1

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- C07D 311/30: not hydrogenated in the hetero ring, e.g. flavones
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/08: Anti-ageing preparations
- C07D 311/32: 2,3-Dihydro derivatives, e.g. flavanones
- C07D 311/40: Separation, e.g. from natural material; Purification
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Described is compound that can be used as an alternative to botulinum neurotoxin and a preparation method thereof, and more specifically, the present invention relates to a myricetin acetyl derivative and a preparation method thereof, wherein the myricetin acetyl derivative has significantly improved stability, including in-vivo stability, and has the ability to inhibit SNARE complex formation, and as a result, to inhibit acetylcholine release.

## Claims

### Claim 1

A composition providing an effect of inhibiting acetylcholine release, the composition comprising 3-acetyl-myricetin being a myricetin derivative represented by the following [Formula 1] as an active ingredient, and

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is a cosmetic composition for aesthetic purposes or a pharmaceutical composition for treatment purposes of disorders caused by excessive release of acetylcholine.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the aesthetic purposes are any one selected from the group consisting of treating wrinkles, reducing pore sizes, and improving skin elasticity.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the disorders caused by the excessive release of acetylcholine are any one selected from the group consisting of crossed eyes, inner ear disorder, teeth grinding, keloid scarring, hyperhidrosis, back pain, tremors, anal fissure, buttock deformity, muscle injuries (twitching), chronic migraine, depression, facial nerve disorder, neck pain (spasms), thyroid disorder, cardiac muscle disorder, upper limb spasticity, pancreas disorders, irritable bowel syndrome, stretch marks, and juvenile cerebral palsy.

### Claim 5

A method for preparing 3-acetyl-myricetin being a myricetin acetyl derivative represented by [Formula 1], the method comprising:
(A) performing a reaction by adding acetic anhydride to myricetin dissolved in pyridine anhydrous under a nitrogen atmosphere sealed to prevent external air and moisture from being introduced;
(B) extracting the synthesized 3-acetyl-myricetin with ethyl acetate (EA);
(C) vacuum-drying the ethyl acetate (EA) extract;
(D) dissolving by adding dimethyl sulfoxide (DMSO) to the vacuum-dried sample and then diluting with phosphate-buffered saline (PBS; pH 7.0);
(E) incubating the diluted sample to decompose by-products; and
(F) freeze-drying the incubated sample.
